Source: ERJ Open Res, 7 (1) 00480-2020; 10.1183/23120541.00480-2020
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Elisabeth Fenwick, Alan Martin, Melanie Schroeder, Stuart J. Mealing, Oyinkansola Solanke, Nancy Risebrough, Afisi S. Ismaila. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res, 7 (1) 00480-2020; 10.1183/23120541.00480-2020

Member's Comments

No comment yet.

Related content which might interest you: Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial Source: ERJ Open Res, 8 (1) 00333-2021; 10.1183/23120541.00333-2021 Year: 2022 The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD Source: Breathe, 14 (4) 333; 10.1183/20734735.026418 Year: 2018 Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009 Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD Source: International Congress 2017 – COPD management Year: 2017 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial Source: Virtual Congress 2021 – Highlights for primary care in 2021 Year: 2021 Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 LAMA/LABA vs. LABA/ICS and triple therapy – is ICS in again? Source: International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose Year: 2018 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 A UK based cost-utility analysis of indacaterol – A once-daily maintenance bronchodilator for patients with COPD Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020 Year: 2021 Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015